TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE C

NCT06311682: A Trial to Evaluate the Efficacy and Safety of Tralokinumab in Combination With Topical Corticosteroids in Children and Infants With Moderate-to-severe Atopic Dermatitis

Sponsor: LEO Pharma · Phase: PHASE3 · Area: DERMATOLOGY_AESTHETIC · Target Enrollment: 195 pts

Competing Trials Overlap

14 Active Trials

Excess Burn Exposure

$2,820,972

Rescue Site Savings

+$1,868,436

Unlock Full NCT06311682 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT06311682 Rescue Dossier →